Molecular structure of Cdk2/9 Inhibitor, CAS Number: 507487-89-0
Cdk2/9 Inhibitor Inhibitor (CAS 507487-89-0)
See product citations (1)
Alternate Names:
4-methyl-5-[2-(3-nitroanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine
Application:
Cdk2/9 Inhibitor is a cell-permeable aminopyrimidinyl compound
CAS Number:
507487-89-0
Molecular Weight:
328.34
Molecular Formula:
C14H12N6O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cdk2/9 Inhibitor is a cell-permeable aminopyrimidinyl compound that acts as a potent ATP-competitive inhibitor of Cdk2/E and Cdk9/T1. It also inhibits GSK-3beta, Cdk4/D, Cdk7/H, Cdk1/B, and Abl at higher concentrations, but exhibits little activity towards 9 other kinases. Cdk2/9 Inhibitor may act to inhibit phosphorylation of cellular Cdk substrates, pRb and RNA polymerase II, and Cdk2-mediated S-phase transition.
Cdk2/9 Inhibitor Inhibitor (CAS 507487-89-0) References
- 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. | Wang, S., et al. 2004. J Med Chem. 47: 1662-75. PMID: 15027857
- Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. | Kontopidis, G., et al. 2006. Chem Biol. 13: 201-11. PMID: 16492568
- Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. | Kawakami, M., et al. 2017. J Natl Cancer Inst. 109: PMID: 28376145
- Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells. | Thomas, AL., et al. 2017. Cell Cycle. 16: 1453-1464. PMID: 28678584
- Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer. | Rao, SS., et al. 2017. Oncotarget. 8: 83925-83939. PMID: 29137393
- Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. | Singh, U., et al. 2017. J Med Chem. 60: 9470-9489. PMID: 29144137
- A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. | Kawakami, M., et al. 2021. Mol Cancer Ther. 20: 477-489. PMID: 33277443
- Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. | Chantkran, W., et al. 2021. Cell Death Discov. 7: 137. PMID: 34112754
- Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. | Chantkran, W., et al. 2021. Cell Death Discov. 7: 171. PMID: 34230455
- Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. | Chen, R., et al. 2022. Leukemia. 36: 1596-1608. PMID: 35383271
- Development and structure-activity relationship of tacrine derivatives as highly potent CDK2/9 inhibitors for the treatment of cancer. | Wu, L., et al. 2022. Eur J Med Chem. 242: 114701. PMID: 36054949
Inhibitor of:
Cdk2, Cdk4, Cdk7, and Cdk9.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdk2/9 Inhibitor, 5 mg | sc-221411 | 5 mg | $416.00 |